Jasper Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update
November 12, 2021
Jasper Therapeutics Announces Research Collaboration with AVROBIO to Evaluate JSP191 as Conditioning Agent in Clinical Studies of Ex Vivo Lentiviral Gene Therapy
November 9, 2021
Jasper Therapeutics to Present at the Credit Suisse 30th Annual Virtual Healthcare Conference
November 8, 2021
Jasper Therapeutics Closes Transaction With Amplitude Healthcare Acquisition Corporation, Creating a Publicly Traded Biotechnology Company Dedicated to Enabling Cures Through Hematopoietic Stem Cell Therapy
September 24, 2021
Amplitude Healthcare Acquisition Corporation Announces Shareholder Approval of Business Combination with Jasper Therapeutics, Inc.
September 22, 2021
Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Two New Board Members
September 20, 2021
Jasper Therapeutics Initiates New Clinical Trial with National Cancer Institute to Evaluate JSP191 in GATA2-related Myelodysplastic Syndromes
September 8, 2021
Jasper Therapeutics and Aruvant Announce Research Collaboration to Study JSP191, an Antibody-Based Conditioning Agent, with ARU-1801, a Novel Gene Therapy for the Treatment of Sickle Cell Disease
June 21, 2021
Jasper Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for JSP191 for Conditioning Treatment Prior to Stem Cell Transplant
June 14, 2021
Jasper Therapeutics to Host Webcast to Review Updated 90-day Data from Phase 1 Clinical Trial of JSP191 That is Being Presented at 2021 ASCO Virtual Annual Meeting
June 1, 2021
Displaying 1 - 10 of 17